Table 2.
Treatment-related adverse events occurring in ≥10% of patients
| Total (n = 39) | ||
|---|---|---|
| Any grade | Grade ≥ 3 | |
| Treatment-related adverse events, n (%) | ||
| Anemia | 35 (89.7) | 8 (20.5) |
| Leukopenia | 31 (79.5) | 22 (56.4) |
| Neutropenia | 24 (61.5) | 16 (41.0) |
| Peripheral neuropathy | 21 (53.8) | 0 (0) |
| Vomiting | 20 (51.3) | 2 (5.1) |
| Nausea | 20 (51.3) | 0 (0) |
| Hypoalbuminemia | 16 (41.0) | 0 (0) |
| ALT increased | 16 (41.0) | 1 (2.6) |
| Skin hyperpigmentation | 15 (38.5) | 0 (0) |
| Hypertriglyceridemia | 15 (38.5) | 0 (0) |
| Fatigue | 14 (35.9) | 1 (2.6) |
| Anorexia | 13 (33.3) | 0 (0) |
| Hyponatremia | 12 (30.8) | 2 (5.1) |
| Diarrhea | 12 (30.8) | 1 (2.6) |
| Rash | 11 (28.2) | 0 (0) |
| AST increased | 11 (28.2) | 2 (5.1) |
| LDH increased | 10 (25.6) | 0 (0) |
| Hypermagnesemia | 10 (25.6) | 0 (0) |
| Oral mucositis | 10 (25.6) | 0 (0) |
| Pruritus | 8 (20.5) | 0 (0) |
| Lymphocytopenia | 7 (17.9) | 1 (2.6) |
| Dry mouth | 7 (17.9) | 0 (0) |
| Cough | 7 (17.9) | 0 (0) |
| Cholesterol high | 7 (17.9) | 0 (0) |
| Hypercalcemia | 7 (17.9) | 0 (0) |
| ALP increased | 6 (15.4) | 0 (0) |
| Pyrexia | 6 (15.4) | 0 (0) |
| Platelet count decreased | 5 (12.8) | 1 (2.6) |
| Hyperglycemia | 5 (12.8) | 0 (0) |
| Hypocalcemia | 5 (12.8) | 0 (0) |
| Hyperuricemia | 5 (12.8) | 0 (0) |
| Somnolence | 5 (12.8) | 0 (0) |
| Hypokalemia | 4 (10.3) | 1 (2.6) |
| Hyperchloremia | 4 (10.3) | 0 (0) |
| Constipation | 4 (10.3) | 0 (0) |
| Headache | 4 (10.3) | 0 (0) |
| Abdominal pain | 4 (10.3) | 0 (0) |
AST aspartate transaminase, LDH lactate dehydrogenase, ALT alanine transaminase.